Literature DB >> 16226110

Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions?

Marianne Lorenzato1, Stephanie Caudroy, Christian Bronner, Ghislaine Evrard, Maryline Simon, Anne Durlach, Philippe Birembaut, Christine Clavel.   

Abstract

The aim of this study on a series of biopsies diagnosed as normal, metaplastic, low-grade squamous intraepithelial lesions (LSILs), and high-grade squamous intraepithelial lesions (HSILs) was dual: to determine the chronology of cell cycle and proliferation abnormalities after human papillomavirus infection during the development of squamous intraepithelial lesions and to determine the best diagnostic indicator(s) linked to the appearance of an HSIL. Ninety-nine cervical biopsies, 18 normal, 9 with metaplastic changes, 29 LSIL, and 43 HSIL (23 cervical intraepithelial neoplasia 2 and 20 cervical intraepithelial neoplasia 3), were analyzed by image cytometry for DNA ploidy and p16INK4A determination, AgNOR counting, MIB-1, and ICBP90 immunostaining quantification. The human papillomavirus status had been previously determined on corresponding cytological smears with the Hybrid Capture II test. Suspect DNA profile and p16INK4A staining were the first significant events that preceded the increase of cell proliferation. Indeed, these markers were the best tests for the detection of a lesion, whatever its grade (positive predictive values of 90% and 100%, respectively). The presence of MIB-1- or ICBP90-positive cells in the upper two thirds of the epithelium was a very accurate feature to select HSIL (sensitivity, 100% for MIB-1) but with a low specificity. The sensitivity of a suspect DNA profile associated with a positive MIB-1 or ICPB90 immunostaining for the detection of an HSIL was, respectively, 92.8% and 92.7%; their specificities were 54.2% and 44%; their positive predictive values were 78% and 73%; their negative predictive values were 81.2% and 78.6%; and the global values were 78.8% and 74.3%. Thus, the most accurate test to distinguish an LSIL from an HSIL was the association of a suspect DNA profile and the presence of MIB-1- or ICBP90-positive cells in the upper two thirds of the epithelium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226110     DOI: 10.1016/j.humpath.2005.07.016

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  26 in total

1.  MOLECULAR MARKERS OF EARLY CERVICAL NEOPLASIA.

Authors:  Alvaro P Pinto; Christopher P Crum; Michelle S Hirsch
Journal:  Diagn Histopathol (Oxf)       Date:  2010-10-01

Review 2.  Our approach to squamous intraepithelial lesions of the uterine cervix.

Authors:  Alexandra N Kalof; Kumarasen Cooper
Journal:  J Clin Pathol       Date:  2006-10-17       Impact factor: 3.411

Review 3.  Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.

Authors:  Mahmoud Alhosin; Tanveer Sharif; Marc Mousli; Nelly Etienne-Selloum; Guy Fuhrmann; Valérie B Schini-Kerth; Christian Bronner
Journal:  J Exp Clin Cancer Res       Date:  2011-04-15

4.  Negative regulation of the acetyltransferase TIP60-p53 interplay by UHRF1 (ubiquitin-like with PHD and RING finger domains 1).

Authors:  Chao Dai; Dingding Shi; Wei Gu
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

5.  UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer.

Authors:  Guo-Liang Yang; Lian-Hua Zhang; Juan-Jie Bo; Hai-Ge Chen; Ming Cao; Dong-Ming Liu; Yi-Ran Huang
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

6.  Overexpression of UHRF1 is significantly associated with poor prognosis in laryngeal squamous cell carcinoma.

Authors:  Jing-Ting Pi; Ye Lin; Qiu Quan; Li-Li Chen; Li-Zhu Jiang; Wang Chi; Hong-Yan Chen
Journal:  Med Oncol       Date:  2013-09-05       Impact factor: 3.064

7.  Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth.

Authors:  Feng Yan; Xiaoming Wang; Lijia Shao; Mengyuan Ge; Xiaoya Hu
Journal:  Tumour Biol       Date:  2015-06-13

8.  UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer.

Authors:  M Unoki; J D Kelly; D E Neal; B A J Ponder; Y Nakamura; R Hamamoto
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

9.  Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation.

Authors:  Zhen-Yu Zhang; Jia-Jun Cai; Jin Hong; Kay Ka-Wai Li; Zhou Ping; Yin Wang; Ho-Keung Ng; Yu Yao; Ying Mao
Journal:  Med Oncol       Date:  2016-07-23       Impact factor: 3.064

Review 10.  p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.

Authors:  I Tsoumpou; M Arbyn; M Kyrgiou; N Wentzensen; G Koliopoulos; P Martin-Hirsch; V Malamou-Mitsi; E Paraskevaidis
Journal:  Cancer Treat Rev       Date:  2009-03-03       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.